BIvideocpd

Name:

Surname:

MP Number:

Email address:

Contact number:

Question 1
What is the predicted global burden of atrial fibrillation (AF) by 2060?

a. 6 841 147

b. 11 178 627

c. 17 900 000

d. 20 234 135

Question 2
How many people over the age of 40 will develop AF?

a. 1 in 5

b. 1 in 4

c. 1 in 6

d. 1 in 2

Question 3
How many times more likely are people with AF to suffer a stroke compared to those without?

a. 5 x

b. 6 x

c. 8 x

d. 10 x

Question 4
Why did the results from the RE-LY® trial introduce a modern era in stroke prevention for the first time in 50 years in patients with AF?

a. Dabigatran was found to be safer than warfarin

b. Dabigatran was found to be more effective than warfarin

c. Dabigatran provided an alternative to warfarin

d. All of the above

Question 5
What study design aspects make the RE-LY® study unique among phase III NOAC (novel oral anticoagulant) trials in patients with AF?

a. Dose and regimen appropriate for dabigatran half-life

b. Global non-inferiority trial with exemplary design and conduct

c. Longest follow-up of a NOAC

d. All of the above

Question 6
What important advantage was demonstrated for dabigatran versus warfarin in the RE-LY® study?

a. Lower rates of stroke with the 110 mg dose

b. Lower risk of ischaemic stroke with the 110 mg dose

c. Lower risk of haemorrhagic stroke with both 110 mg and 150 mg dose

d. All of the above

Question 7
Which of the following NOACs demonstrate a greater reduction in ischaemic stroke compared to warfarin?

a. Apixaban

b. Dabigatran 150 mg BD

c. Dabigatran 110 mg

d. Rivaroxaban

Question 8
Which of the following NOACs demonstrate a greater reduction in haemorrhagic stroke compared to warfarin?

a. Dabigatran

b. Apixaban

c. Rivaroxaban

d. All of the above

Question 9
What is the reduction in risk of ischaemic stroke achieved by apixaban and rivaroxaban compared to warfarin?

a. Similar

b. Significantly higher

c. Significantly lower

d. Not known

Question 10
Which of the following NOACs demonstrate a greater reduction in cardiovascular mortality compared to warfarin?

a. Apixaban

b. Dabigatran 110 mg

c. Dabigatran 150 mg BD

d. Rivaroxaban